bims-exocan Biomed News
on Exosomes roles in cancer
Issue of 2026–06–21
six papers selected by
Muhammad Rizwan, COMSATS University



  1. Mol Cell Probes. 2026 Jun 17. pii: S0890-8508(26)00016-2. [Epub ahead of print]89 102076
       BACKGROUND: The low early diagnostic efficacy of non-small cell lung cancer (NSCLC) is a key contributor to its high mortality rate, and small nucleolar RNAs (snoRNAs) in serum exosomes can serve as a beneficial liquid biopsy approach for the early diagnosis of NSCLC.
    METHODS: Exosomes were isolated from collected serum; their morphology was imaged using transmission electron microscopy (TEM); particle size was measured using a particle size analyzer; and the expression of exosomal membrane proteins was identified using Western blot. Gene chips were used to screen for differentially expressed snoRNAs in exosomes, which were further validated by quantitative PCR (qPCR). The area under the receiver operating characteristic (ROC) curve (AUC) was used to estimate their diagnostic performance for NSCLC. Their biological functions in NSCLC were evaluated using an in vitro study.
    RESULTS: A series of exosome characterization experiments confirmed successful exosome extraction. Microarray and qPCR analyses revealed that serum exosomal snoRNAs (AC092799.1-201 and AC009408.1-201) were significantly upregulated in individuals with NSCLC. When combined with CEA and CYFRA21-1, these two exosomal snoRNAs achieved diagnostic efficacy of 0.948 and early diagnostic efficacy of 0.917. Cell experiments confirmed that AC092799.1-201 is related to rapid proliferation and high invasiveness of tumor cells.
    CONCLUSION: Exosomal snoRNAs AC092799.1-201 and AC009408.1-201, merged with CEA and CYFRA21-1, can serve as a novel liquid biopsy approach for the early diagnosis of NSCLC.
    Keywords:  Early diagnosis; Exosomes; NSCLC; snoRNA
    DOI:  https://doi.org/10.1016/j.mcp.2026.102076
  2. Anticancer Agents Med Chem. 2026 Jun 18.
       INTRODUCTION: Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanoscale, lipid bilayer-enclosed particles released by diverse cell types. They play a key role in intercellular communication by transferring proteins, lipids, and nucleic acids. In cancer, EVs contribute to remodelling the tumor microenvironment, enhancing angiogenesis, modulating immune responses, promoting metastasis, and driving therapeutic resistance.
    AIM: This narrative review aims to highlight the biological importance and clinical relevance of EVs in cancer, focusing on their potential as biomarkers and therapeutic tools.
    METHODS: A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science. Studies on EV composition, isolation, and characterization methods, as well as recent advances in EV bioengineering, were critically examined to summarize their significance in oncology.
    RESULTS AND DISCUSSION: Findings reveal that the molecular cargo of EVs reflects the physiological and pathological states of their source cells, supporting their role as non-invasive biomarkers for cancer detection and monitoring. EVs also regulate signaling pathways that sustain tumor heterogeneity and adaptability. Moreover, engineered EVs demonstrate strong potential as delivery systems for chemotherapeutic agents, RNA-based drugs, and immunomodulators, underscoring their translational value in targeted therapy.
    CONCLUSION: EVs represent versatile tools in precision oncology. Although standardization and clinical validation remain challenges, ongoing research and technological progress may establish EV-based strategies as integral components of personalized cancer treatment.
    Keywords:  EV Cargo; Extracellular vesicles; cancer.; exosomes; microvesicles; niche formation
    DOI:  https://doi.org/10.2174/0118715206434074260407093116
  3. Transl Cancer Res. 2026 May 30. 15(5): 438
       Background and Objective: Exosomes, as key mediators of intercellular communication, carry microRNAs (miRNAs) that play central roles in anticancer drug resistance by regulating the immune status of the tumor microenvironment (TME) and drug-metabolic pathways. In recent years, advances in single vesicle analysis have greatly promoted mechanistic studies on exosomal miRNAs in diffuse large B-cell lymphoma (DLBCL). This article aims to comprehensively review recent advances in the study of exosomal miRNAs in DLBCL. This review explores the value of exosomal miRNAs as tumor biomarkers in diagnosis and prognostic evaluation of DLBCL, and provides an in-depth analysis of molecular networks underlying DLBCL drug resistance mediated through exosomal miRNAs.
    Methods: This study conducted a literature review by searching the PubMed and Web of Science databases to identify the latest research findings regarding the roles of exosomal miRNAs as tumor biomarkers in diagnosis and prognostic evaluation of DLBCL, and the mechanisms by which exosomal miRNAs regulates DLBCL drug resistance. Based on these findings, a narrative review was generated.
    Key Content and Findings: This article introduces the biogenesis of exosomal miRNA and research progress on exosomal miRNAs as biomarkers in the diagnosis and prognosis of DLBCL. It summarizes the research progress on the mechanisms of exosomal miRNA in regulating therapeutic resistance in DLBCL. And it also discusses the current translational studies using exosomal miRNAs to control drug resistance in DLBCL, and challenges of using extracellular vesicle (EV)-derived miRNAs. These advances will help provide more new strategy for reversing DLBCL drug resistance in the future.
    Conclusions: Exosomal miRNAs can serve as biomarkers for the diagnosis and prognostic assessment of DLBCL and are associated with DLBCL treatment resistance. Currently, there has been significant progress in research on the mechanisms by which exosomal miRNAs regulate DLBCL resistance, with some mechanisms already validated. It is expected that through more in-depth in vivo and in vitro studies in the future, mature therapeutic targets can be developed.
    Keywords:  Exosomal miRNAs; biomarkers; diffuse large B-cell lymphoma (DLBCL); drug resistance; tumor microenvironment (TME)
    DOI:  https://doi.org/10.21037/tcr-2026-0532
  4. Mol Cancer. 2026 Jun 20.
      Extracellular vesicles (EVs) are important mediators of intercellular communication in solid tumors. Released by malignant, stromal, immune, and microbial cells, they influence tumor evolution by transferring proteins, nucleic acids, lipids, and metabolites that reshape local and systemic signaling. Current evidence implicates EVs in tumor microenvironment remodeling, metastatic niche formation, immune regulation, and adaptive responses to metabolic and therapeutic stress. However, these functions are highly context-dependent and remain unevenly supported across tumor types, disease stages, and experimental systems. Mechanistically, EV production is increasingly understood not as a constitutive secretory event, but as an adaptive output of intracellular trafficking and metabolic programs that govern vesicle fate, cargo selection, and release under stress. The same properties that complicate biological interpretation-including heterogeneity, membrane plasticity, and context-dependent cargo sorting-also make EVs attractive candidates for therapeutic engineering. In this Review, we critically examine EV biology in solid tumors by connecting biogenesis, trafficking control, lipid metabolism, and functional heterogeneity with emerging engineering strategies, including source selection, surface modification, cargo loading, and hybrid engineering strategies. We further discuss the major barriers that continue to limit clinical translation, particularly biological heterogeneity, isolation-dependent variability, incomplete mechanistic resolution, manufacturing scalability, and regulatory standardization. By distinguishing more established principles from emerging or model-restricted findings, this Review aims to provide a balanced assessment of both the opportunities and the current limitations of EV-based diagnostics and therapeutics.
    Keywords:  Cancer immunotherapy; Drug delivery; EV engineering; Extracellular vesicles; Liquid biopsy; Metastasis; Solid tumors; Therapy resistance; Translational challenges; Tumor microenvironment
    DOI:  https://doi.org/10.1186/s12943-026-02705-7
  5. Transl Lung Cancer Res. 2026 May 31. 15(5): 152
       Background and Objective: Lung cancer is one of the most common malignant tumors in the world, with a high incidence and a poor prognosis. The current treatment methods are limited, and novel treatment strategies are needed. Macrophages, as innate immune cells, interact with lung cancer cells in the tumor microenvironment and can influence the occurrence and development of lung cancer. This paper reviews the role of macrophages in lung cancer in relation to polarization, exosomes, cytokines, cell pathways and genes, and clinical prognosis.
    Methods: A structured literature search of PubMed, Web of Science Core Collection, and Embase was conducted from database inception to February 6, 2026. This was supplemented by cross-checking in Google Scholar and manual screening of reference lists from key reviews and landmark studies. Two authors independently screened titles and abstracts, and full texts were assessed according to designated inclusion criteria.
    Key Content and Findings: A comprehensively review of the multifaceted roles of macrophages in lung cancer development, progression, and therapeutic response was conducted. The origin and phenotypic polarization of macrophages were examined, with the functional heterogeneity between antitumor M1 macrophages and protumor M2 tumor-associated macrophages (TAMs) within the tumor microenvironment emerging as a prominent topic. Another important theme was the crosstalk between macrophages and lung cancer cells mediated by exosomes, inflammatory cytokines, and key signaling pathways, including NF-κB, STAT3/STAT6, and PI3K/AKT, as well as gene regulatory mechanisms. These interactions collectively promote tumor growth, angiogenesis, metastasis, immune suppression, and therapy resistance. Furthermore, the clinical and prognostic significance of macrophage infiltration patterns and polarization status in patients with lung cancer was examined. Overall, the targeting of macrophage polarization and macrophage-related signaling networks emerged as a promising strategy for improving lung cancer diagnosis, prognosis assessment, and immunotherapeutic outcomes.
    Conclusions: Macrophages act as central regulators of lung cancer progression and therapeutic response through their remarkable plasticity within the tumor microenvironment. The balance between antitumor M1 and protumor M2 macrophages, shaped by exosomes, cytokines, signaling pathways, and gene regulation, critically influences tumor growth, metastasis, immune evasion, and prognosis. Targeting macrophage polarization and macrophage-related pathways represents a promising strategy for improving the diagnosis of patients with lung through achieving more accurate prognostic evaluation and greater treatment efficacy.
    Keywords:  Lung cancer; exosomes; macrophage; pathway; polarization
    DOI:  https://doi.org/10.21037/tlcr-2026-0418
  6. Biochim Biophys Acta Rev Cancer. 2026 Jun 15. pii: S0304-419X(26)00108-3. [Epub ahead of print]1881(4): 189636
      Head and neck squamous cell carcinoma (HNSCC) is the seventh most frequently diagnosed cancer worldwide, contributing to approximately 400,000 deaths annually. Recently, the involvement of human papillomavirus (HPV) in the etiopathogenesis of this malignancy, particularly in oropharyngeal squamous cell carcinoma (OPSCC), has been emphasized. In parallel, the potential role of extracellular vesicles (EVs) in the initiation and progression of HNSCCassociated with HPV infection has emerged. EVs are small, membrane-bound vesicles secreted by all cell types, that transport biologically significant cargo, including proteins and nucleic acids. EVs produced by tumor cells interact with non-malignant cells and reprogram the tumor microenvironment, inducing immune suppression, promoting angiogenesis, and facilitating tumor metastasis. Tumor-derived EVs carry DNA and may be responsible for the horizontal transfer of viral structural and functional components, including the E6 and E7 oncoproteins to other cells. The interplay between the mechanisms associated with the HPV replication cycle, EV biogenesis and release, and carcinogenesis represents a novel and still poorly understood area in the investigation of HNSCC development and progression. This review synthesizes recent findings on the distinct roles tumor-derived EVs appear to play in both HPV-dependent and HPV-independent HNSCC.
    Keywords:  Exosomes; Extracellular vesicles; HPV infection; Head and neck cancer; Human papilloma virus
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189636